Community pharmacist–provided care for minor conditions could be cost-effective, new research shows.

Does taking the GLP-1 receptor agonist semaglutide for blood glucose control also lower the risk of clinically important kidney and cardiovascular outcomes? In the FLOW clinical trial, researchers found that of the 3,533 patients diagnosed with both T2D and chronic kidney disease, those taking semaglutide had a 24% lower risk of a primary-outcome event in the intervention group compared with the controls.

University of Florida Health has been awarded a stipend by CDC to run a program that aims to connect patients with high BP to community pharmacists.

Law enforcement seizures of illicit fentanyl increased dramatically in number and size between 2017 and 2023 in the United States, especially in tablet form, according to a new study funded by the NIH National Institute on Drug Abuse. The findings, published online in International Journal of Drug Policy on May 13, 2024, highlight the illicit drug supply and the risk of tablets not coming from a pharmacy.

Despite concerns about patients regaining weight after stopping GLP-1 receptor agonists like semaglutide and tirzepatide, new research suggests that such gains aren’t necessarily the case. The key, the findings suggest, lies in gradually weaning off the drug instead of withdrawing abruptly and completely, and then continuing to make healthy choices.